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ABSTRACT 
 
Anterior cruciate ligament (ACL)-to-bone interface serves to minimize the stress concentrations that 
would arise between two different tissues. Mechanical stretch plays an important role in maintaining 
cell-specific features by inducing CCN family 2/connective tissue growth factor (CCN2/CTGF). We 
previously reported that cyclic tensile strain (CTS) stimulates α1(I) collagen (COL1A1) expression in 
human ACL-derived cells. However, the biological function and stress-related response of 
CCN2/CTGF were still unclear in ACL fibroblasts. In the present study, CCN2/CTGF was observed in 
ACL-to-bone interface, but was not in the midsubstance region by immunohistochemical analyses. 
CTS treatments induced higher increase of CCN2/CTGF expression and secretion in interface cells 
compared with midsubstance cells. COL1A1 expression was not influenced by CCN2/CTGF treatment 
in interface cells despite CCN2/CTGF stimulated COL1A1 expression in midsubstance cells. However, 
CCN2/CTGF stimulated the proliferation of interface cells. Our results suggest that distinct biological 
function of stretch-induced CCN2/CTGF might regulate region-specific phenotypes of ACL-derived 
cells. 
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1. Introduction 
CCN family 2/connective tissue growth factor (CCN2/CTGF) is a multifunctional regulator of cellular 
proliferation, differentiation, and tissue regeneration [1]. Ccn2/ctgf-null mice are perinatal lethal, 
showing severe chondrodisplasia characterized by deficient extracellular matrix (ECM) production, 
impaired endochondral ossification, and reduced growth plate angiogenesis [2]. These phenotypes 
indicate that CCN2/CTGF plays an essential role in skeletal development during embryogenesis. In 
the adult, the expression of CCN2/CTGF is associated with injury repair and inflammation [3]. Several 
studies have reported that CCN2/CTGF promotes the proliferation of vascular endothelial cells [4], 
chondrocytes [5], osteoblastic cells [6], and periodontal ligament cells [7]. In addition, CCN2/CTGF is 
known to stimulate cellular differentiation and ECM synthesis as well in these cells [5-7]. However, 
the expression pattern and function of CCN2/CTGF in human ligament tissues remain unclear. 
Anterior cruciate ligament (ACL) injuries usually occur in the femoral attachment of ACL 
that contains interface cells [8]. Those cells in ACL-to-bone insertion have more chondrocytic 
phenotypes compared with midsubstance cells in the middle part of ACL [9,10]. ACL-to-bone 
interface has a specific structure called fibrocartilaginous enthesis that is composed of four different 
regions; dense fibrous connective tissue (ligament), uncalcified fibrocartilage, calcified fibrocartilage, 
and subchondral bone [11,12]. Fibrocartilaginous enthesis serves to minimize the stress concentrations 
that would arise between the two different tissues, such as extensible tendon/ligament and rigid bone 
[13,14]. We have previously reported that cyclic tensile strain (CTS) stimulates α1(I) collagen gene 
(COL1A1) expression in both interface and midsubstance cells derived from human ACL [15]. In this 
literature, stretching treatment induced higher increase of COL1A1 expression in interface cells rather 
than in midsubstance cells [15]. These findings suggest that mechanical stretch has a crucial role in 
maintaining the homeostasis of ACL and ACL-to-bone interface [16]. 
The ligaments have stress-oriented structures of collagen bundles [17]. Type I collagen is the 
main component of ECM in the ligaments [18]. Type II and III collagens play important roles for the 
maturation of ligament-to-bone interface zones [12,19]. Biomechanical studies have shown that the 
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length of human ACL is exposed to 12% elongation at 90 degrees of knee flexion [17]. Human 
cadaveric ACL-to-bone units fail at a mean strain level of 19% by a material testing system [20]. In 
human ACL cells, uni-axial 10% CTS increases the gene expression of type I and III collagens 
mediated by the autocrine secretion of transforming growth factor (TGF)-β1 [21]. However, the 
biological function and mechanical stretch-related response of CCN2/CTGF are still unclear in ACL 
fibroblasts. Effect of mechanical strain on CCN2/CTGF expression is dependent on cell types and 
stretching force. Cyclic stretch (0.3 Hz, 15% strain) stimulates the expression of COL1A1 and 
CCN2/CTGF in human bladder smooth muscle cells [22]. In human chondrocytic HCS-2/8 cells, CTS 
(0.16 Hz, 6% strain) increases CCN2/CTGF gene expression [23]. On the other hand, cyclic stretch 
(0.16 Hz, 20% strain) decreases CCN2/CTGF expression in human skin fibroblasts [24]. In loading 
stress, the expressions of COL1A1, TGF-β1, and CCN2/CTGF in rat soleus muscles are increased 
despite TGF-β1 and CCN2/CTGF expressions in rat Achilles tendons are unaltered [25]. 
In the present study, we investigated the localization of CCN2/CTGF in human ACL tissues 
and evaluated its expression in response to mechanical stretch in human ACL-derived cells, in order to 
clarify the role of CCN2/CTGF in COL1A1 expression and the proliferation of ACL-derived cells. 
 
2. Materials and methods 
2.1. Cells and cell culture 
Institutional Review Board approval was obtained for this study. Informed consents for this research 
were also obtained from patients. Human ACL fibroblasts were isolated from intact femur-ACL-tibia 
samples obtained at total knee arthroplasties in patients suffering from osteoarthritis (n = 6). Patients 
included five females and one male, with a mean age of 65 years (range, 62-72 years) at the time of 
surgery. Surrounding synovial tissues and attached bones were carefully removed from ACL samples. 
ACL-derived interface cells were isolated from 5-mm-segments of ACL-to-bone junctions (femoral 
and tibial interfaces) as described [15]. The remaining ligament was used as ACL-derived 
midsubstance cells. The ligament samples were minced, and incubated with collagenase (Sigma, 
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St.Luis, MO) for 30 min at 37°C as described [26]. The mixtures were filtered through 70 μm cell 
strainers (BD Biosciences, Bedford, MA). The flow through suspension was cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Wako, Osaka, Japan) containing 10% fetal bovine serum (HyClone, 
South Logan, UT) and 1% penicillin/streptomycin (Sigma). Attached cells were incubated at 37°C in 
5% CO2 in a humidified atmosphere and were subcultured at a density of 2,500 cells/cm2 on uncoated 
polystyrene tissue culture dishes (BD Biosciences). The medium was changed every 3 days. Cells 
between passage 2 and 5 were used for experiments. 
2.2. RT-PCR and quantitative real-time PCR analysis 
Total RNA was isolated using ISOGEN reagent (Nippon Gene, Toyama, Japan). RNA samples 
obtained from tissue samples and cultured cells were reverse-transcribed with ReverTra Ace (Toyobo, 
Osaka, Japan). The cDNAs underwent PCR amplification in the presence of each set of specific 
primers using rTaq DNA polymerase (TaKaRa, Ohtsu, Japan). The following specific primer sets were 
used: 5’-CCACC CGAGT TACCA ATGAC-3’ and 5′-GTGCA GCCAG AAAGC TCA-3′ for 
CCN2/CTGF; COL1A1 and glyceraldehyde-3-phosphate dehydrogenase (G3PDH) as described 
previously [27]. For all the RT-PCR fragments, the reactions were allowed to proceed for 30 cycles in 
an iCycler thermal cycler (Bio-Rad Laboratories, Hercules, CA). Quantitative real-time PCR analyses 
were performed by using LightCycler ST-300 instrument (Roche Diagnostics, Mannheim, Germany) 
and FastStart DNA Master SYBR Green I kit (Roche Diagnostics) according to the manufacturer’s 
protocol. The cycle number crossing the signal threshold was selected in the linear part of the 
amplification curve. Amplification data of G3PDH were used for normalization. 
2.3. Cyclic tensile strain (CTS) 
Polydimethylsiloxane stretch chambers (STREX, Osaka, Japan) were coated with 50 μg/ml fibronectin 
(Chemicon, Temecula, CA). Midsubstance and interface cells were seeded onto stretch chambers, each 
having a culture surface of 2×2 cm, at the concentration of 50,000 cells/chamber. The cells were 
incubated on fibronectin-coated chambers for 24 h before stretching experiments. Uni-axial CTS (0.5 
Hz, 10% strain) was applied using a STB-140 system (STREX) for 1, 2, and 4 h as described [15]. 
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Non-stretched ACL cells cultured on stretch chambers were used as controls. RNAs and conditioned 
media were immediately collected after stretching experiments. 
2.4. Histology and immunohistochemistry 
To investigate the localization of CCN2/CTGF in human ACL, tissue samples obtained from surgical 
specimen under written informed consent were fixed with 4% paraformaldehyde solutions for 24 h and 
were embedded in paraffin. Sections were cut into 5 μm-thickness and were stained with hematoxylin 
and eosin (HE) for standard light microscopy. Anti-CCN2/CTGF antibodies purified from rabbits by 
immunization with a synthetic peptide of CCN2/CTGF (RPCEA DLEEN IKKGK KCIRT) were used 
for immunohistochemical analyses as described [5,28]. 
2.5. Enzyme-linked immunosorbent assay (ELISA) 
The concentration of CCN2/CTGF in conditioned media was measured by using a sandwich ELISA 
system with two anti-human CCN2/CTGF monoclonal antibodies (MAb 8-64 and 8-86; mouse IgG1, 
Nichirei, Tokyo, Japan) as described previously [29]. In brief, samples were applied to ELISA strips 
coated with MAb 8-64 and incubated for 2 h. After 6 cycles of washing, horseradish 
peroxidase-conjugated MAb 8-86 was added, and the strips were incubated for 1 h. The signals were 
developed by an enzymatic reaction with tetramethylbenzidine. 
2.6. CCN2/CTGF treatment and cell proliferation assay 
Cells were cultured on fibronectin-coated plates for 12 h in serum-free DMEM before the treatment 
with recombinant human CCN2/CTGF (BioVender, Candler, NC). CCN2/CTGF treatment (10 or 50 
ng/ml) was performed for 4 h before the preparation of RNA samples. Cell proliferation assays were 
performed as described previously [30,31]. In brief, recombinant human CCN2/CTGF was added into 
serum-free DMEM at indicated concentrations. ACL cells (5,000 cells/well) were incubated for 48 h 
prior to addition of WST-1 (Roche Diagnostics) on 96-well plates. Optical density (OD) was measured 
by using a Model 550 microplate reader (Bio-Rad, Hercules, CA) at evaluation and control 
wavelengths of 450 nm and 630 nm, respectively. Data obtained by subtracting 630-nm readings from 
450-nm readings were used for evaluation. The mean value derived from four wells was computed and 
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plotted. 
2.7. Statistical analysis  
All experiments were repeated at least three times and similar results were obtained. Data were 
expressed as mean values with standard deviations. Differences among groups were compared by 
using the Mann-Whitney U-test. Statistical significance was established at p < 0.05. 
 
3. Results 
3.1. Localization of CCN2/CTGF in human ACL 
We initially investigated the presence and distribution of CCN2/CTGF in human ACL tissues. 
CCN2/CTGF was observed in the ACL-to-bone interface, but was not in the midsubstance region by 
immunohistochemical analyses (Fig. 1C and D). Cells packaged in interface regions were stained by 
anti-CCN2/CTGF antibody (Fig. 1E and F), whereas CCN2/CTGF was not significantly detected in 
the ECM of tibial and femoral interface regions (Fig. 1E and F). 
 
3.2. Differences between interface and midsubstance cells in morphology and CCN2/CTGF production 
Interface cells had different features from those of midsubstance cells. The morphology of interface 
cells in culture was typically characterized by a triangular shape (Fig. 2A). On the other hand, 
midsubstance cells had a fibroblastic morphology (Fig. 2A). Interestingly, the expression of 
CCN2/CTGF in respective cells showed different patterns from those in tissue samples, when they 
were brought into cell culture in vitro (Fig. 2B). Despite CCN2/CTGF was present in the tissues of 
interface region, RT-PCR analyses revealed that CCN2/CTGF expression was remarkably decreased in 
interface-derived cells, (Fig. 2B), which was efficiently recovered by CTS (Fig. 2C and D). CTS also 
increased CCN2/CTGF secretion from interface cells (Fig. 2F). On the other hand, CTS treatment did 
not increase the gene expression of CCN2/CTGF (Fig. 2C and D) and CCN2/CTGF secretion (Fig. 2F) 
in midsubstance cells. These results represent distinct biological characteristics of these 2 types of 
ACL-derived cells. Consistent with our previous findings [15], COL1A1 expression was enhanced by 
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CTS treatment in both interface and midsubstance cells (Fig. 2C and E). 
 
3.3. Functional role of CCN2/CTGF in interface cells 
As more pronounced CTS-induced CCN2/CTGF expression was observed in interface cells, we 
further investigated the biological role of CCN2/CTGF in ACL cells. Recombinant CCN2/CTGF 
treatment increased the expression of endogenous CCN2/CTGF gene only in interface cells (Fig. 3A 
and B). Surprisingly, COL1A1 expression was not influenced by CCN2/CTGF treatment alone in 
interface cells despite CCN2/CTGF stimulated COL1A1 expression in midsubstance cells (Fig. 3C). 
However, importantly, CCN2/CTGF significantly stimulated the proliferation of interface cells in a 
dose-dependent manner (Fig. 3D). These findings suggest that stretch-induced CCN2/CTGF might act 
as an activator for cellular proliferation, not for type I collagen production, in ACL-to-bone interface. 
 
4. Discussion 
CCN2/CTGF stimulates collagen gene expression in several types of cells such as chondrocytes, 
osteoblastic cells, periodontal ligament cells, and astrocytes [5-7,32,33]. Mechanical stretch also has a 
critical role in enhancing COL1A1 expression in ligament fibroblasts [15,21,34]. Yang et al. have 
described that cyclic stretch increases the expression of CCN2/CTGF and COL1A1 in bladder smooth 
muscle cells [22]. However, the relationship between CCN2/CTGF and stretch-induced COL1A1 
expression remains unclear. We have previously reported that CTS induces higher increase of 
COL1A1 expression in human ACL interface cells, rather than in midsubstance cells [15]. In the 
present study, we demonstrated that CCN2/CTGF was localized in human ACL-to-bone interface (Fig. 
1). CTS also promoted the expression of CCN2/CTGF in interface cells (Fig. 2). In addition, 
recombinant CCN2/CTGF stimulated endogenous CCN2/CTGF expression and cellular proliferation 
of interface cells, while COL1A1 expression was not affected by CCN2/CTGF treatment in the 
absence of mechanical stretch (Fig. 3). These findings suggest that stretch-mediated COL1A1 
transactivation might not directly depend on stretch-induced CCN2/CTGF production in ACL 
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interface cells. Considering the molecular property of CCN2/CTGF that promotes physiological 
process of tissue development and regeneration under multiple molecular interactions, CCN2/CTGF is 
expected to enhance the proliferation of interface cells in the absence of mechanical stretch, and type I 
collagen production of interface cells under stretched condition. 
ACL-to-bone interface, characterized as fibrocartilaginous enthesis, shifts its characteristics 
from proliferative to hypertrophic zone of the growth plate during development [12,19]. 
Age-dependent changes in collagen deposition (from type II collagen to type X collagen) are observed 
at the interface [12]. Our previous study has indicated that cells in the interface zone of aged ACLs 
still express α1(II) collagen (COL2A1) gene in three-dimensional tissue culture conditions (in vivo) 
[15]. In two-dimensional cell culture conditions (in vitro), non-stretched interface cells lose their 
potential to produce COL2A1 gene [15]. However, CTS induces COL2A1 re-expression in cultured 
interface cells [15]. The present study demonstrated that CTS treatment recovered the expression of 
CCN2/CTGF despite CCN2/CTGF expression was decreased in cultured interface cells (Fig. 2). In 
human chondrocytic HCS-2/8 cells, CCN2/CTGF expression is increased by CTS [23]; then 
CCN2/CTGF enhances the expression of the Col2a1 and aggrecan genes in rabbit growth plate and 
articular chondrocytes, as well as in HCS-2/8 cells [5,35]. These findings suggest that the 
fibrocartilaginous property of ACL-to-bone interface might be maintained by mechanical 
stretch-induced CCN2/CTGF. 
Cellular responses to mechanical stress underlie many critical functions such as development, 
morphogenesis, hypertension, and wound healing [36]. In experimental studies, physiological force 
has been mimicked by various mechanical stimuli, including stretch, compression, shear stress, and 
bending torque [36]. Cell stretch would induce mechanical extension of cytoplasmic macromolecules, 
activation of ion channels, and phosphorylation of mechanotransducers [36-38]. However, cellular 
behavior is not uniform under comparable stretching condition in vitro. CCN2/CTGF expression is 
increased by cyclic stretch (no more than 15% strain) in bladder smooth muscle cells and chondrocytic 
cells [22,23]. On the other hand, 20% length of cellular stretch rather decreases CCN2/CTGF 
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expression in skin fibroblasts [24]. In our experiments, the degree of stretching force (5-15%) 
influenced the expression pattern of CCN2/CTGF and COL1A1 genes (Supplemental Fig.). The 
expression of CCN2/CTGF and COL1A1 was highly activated under 10% CTS condition in ACL 
interface cells (Supplemental Fig. and 2). Physiological stretching force might be important for 
inducing optimum production of CCN2/CTGF and ECM molecules to maintain ligament homeostasis. 
Cell morphology and actin cytoskeleton under various mechanical forces also regulate CCN2/CTGF 
expression [39]. In three-dimensional-cultured human lung fibroblasts, stretch-induced CCN2/CTGF 
expression is decreased by a specific inhibitor of RhoA/ROCK signaling pathway that modulates actin 
cytoskeleton [40]. Cyclic stretch-stimulated CCN2/CTGF promoter activity is suppressed by a 
RhoA/ROCK inhibitor in bovine bladder smooth muscle cells [41]. Mouse adipose-derived stromal 
cells produce higher levels of CCN2/CTGF and RhoA proteins in a low-density (spread) culture 
condition compared with a high-density-seeded condition [42]. On the other hand, CCN2/CTGF 
expression is not affected by a RhoA/ROCK inhibitor, but is down-regulated by a Rac1 inhibitor in 
mouse primary chondrocytes [43]. In our previous study, CTS activates integrin αVβ3-mediated stress 
fiber formation on fibronectin-coated chambers in human ACL fibroblasts [15]. From these findings, 
stretch-associated cytoskeletal tension, which is cooperatively modulated by several intracellular 
signaling pathways, may play an important role in CCN2/CTGF expression. Further studies will be 
required to clarify the relationships among stretch-activated signaling pathways, CCN2/CTGF 
expression, and ECM synthesis in ACL fibroblasts. 
 In conclusion, our results demonstrated that mechanical stretch stimulated the gene 
expression and synthesis of CCN2/CTGF in ACL-to-bone interface cells. Interface cell proliferation 
and COL1A1 expression in midsubstance cells were also enhanced by CCN2/CTGF treatments in the 
absence of CTS. These findings suggest that stretch-mediated CCN2/CTGF production might have a 
crucial role in regulating region-specific phenotypes of ACL-to-bone interface. 
 
 
11 
 
Acknowledgements 
We thank Ms. Motomi Hachioji, Dr. Aki Yoshida, and Dr. Eriko Aoyama for their kind cooperation. 
We are also grateful to Dr. Nobuhiro Abe for providing tissue samples. This work was supported by 
Japan Society for the Promotion of Science (Nos. 19109008, 20791040, and 21592360), JSPS Fujita 
Memorial Fund for Medical Research, the Japanese Foundation for Research and Promotion of 
Endoscopy, Okayama Medical Foundation, Japan Orthopaedics and Traumatology Foundation (No. 
225), and Child Health and Development from the Ministry of Health, Labor and Welfare. 
 
References 
1. B. Perbal, M. Takigawa (Eds.), CCN proteins: a new family of cell growth and differentiation 
regulators, Imperial College Press, London, 2005. 
2. S. Ivkovic, B.S. Yoon, S.N. Popoff, et al., 2003. Connective tissue growth factor coordinates 
chondrogenesis and angiogenesis during skeletal development, Development 130 (2003) 
2779-2791. 
3. C.C. Chen, L.F. Lau, Functions and mechanisms of action of CCN matricellular proteins, Int. J. 
Biochem. Cell Biol. 41 (2009) 771-783. 
4. T. Shimo, T. Nakanishi, T. Nishida, et al., Connective tissue growth factor induces the 
proliferation, migration, and tube formation of vascular endothelial cells in vitro, and 
angiogenesis in vivo, J. Biochem. 126 (1999) 137-145. 
5. T. Nakanishi, T. Nishida, T. Shimo, et al., Effects of CTGF/Hcs24, a product of a hypertrophic 
chondrocyte-specific gene, on the proliferation and differentiation of chondrocytes in culture, 
Endocrinology 141 (2000) 264-273. 
6. T. Nishida, T. Nakanishi, M. Asano, et al., Effects of CTGF/Hcs24, a hypertrophic 
chondrocyte-specific gene product, on the proliferation and differentiation of osteoblastic cells in 
vitro, J. Cell. Physiol. 184 (2000) 197-206. 
7. M. Asano, S. Kubota, T. Nakanishi, et al., Effect of connective tissue growth factor 
12 
 
(CCN2/CTGF) on proliferation and differentiation of mouse periodontal ligament-derived cells, 
Cell Commun. Signal 3 (2000) 11. 
8. T. Zantop, P.U. Brucker, A. Vidal, et al., Intraarticular rupture pattern of the ACL, Clin. Orthop. 
Relat. Res. 454 (2007) 48-53. 
9. I.E. Wang, J. Shan, R. Choi, et al., Role of osteoblast-fibroblast interactions in the formation of 
the ligament-to-bone interface, J. Orthop. Res. 25 (2007) 1609-1620. 
10. T. Furumatsu, M. Hachioji, K. Saiga, et al., Anterior cruciate ligament-derived cells have high 
chondrogenic potential, Biochem. Biophys. Res. Commun. 391 (2010) 1142-1147. 
11. M. Benjamin, D. McGonagle, The anatomical basis for disease localisation in seronegative 
spondyloarthropathy at entheses and related sites, J. Anat. 199 (2001) 503-526. 
12. I.E. Wang, S. Mitroo, F.H. Chen, et al., Age-dependent changes in matrix composition and 
organization at the ligament-to-bone insertion, J. Orthop. Res. 24 (2006) 1745-1755. 
13. S. Thomopoulos, G.R. Williams, J.A. Gimbel, et al., Variation of biomechanical, structural, and 
compositional properties along the tendon to bone insertion site, J. Orthop. Res. 3 (2003) 
413-419. 
14. S. Thomopoulos, J.P. Marquez, B. Weinberger, et al., Collagen fiber orientation at the tendon to 
bone insertion and its influence on stress concentrations, J. Biomech. 39 (2006) 1842-1851. 
15. T. Tetsunaga, T. Furumatsu, N. Abe, et al., Mechanical stretch stimulates integrin 
αVβ3-mediated collagen expression in human anterior cruciate ligament cells, J. Biomech. 42 
(2009) 2097-2103. 
16. D.R. Henshaw, E. Attia, M. Bhargava, J.A. Hannafin, Canine ACL fibroblast integrin expression 
and cell alignment in response to cyclic tensile strain in three-dimensional collagen gels, J. 
Orthop. Res. 24 (2006) 481-490. 
17. V.B. Duthon, C. Barea, C. Abrassart, et al., Anatomy of the anterior cruciate ligament, Knee Surg. 
Sports Traumatol. Arthrosc. 14 (2006) 204-213. 
18. A.J. Almarza, S.M. Augustine, S.L. Woo, Changes in gene expression of matrix constituents with 
13 
 
respect to passage of ligament and tendon fibroblasts, Ann. Biomed. Eng. 36 (2008) 1927-1933. 
19. K. Nawata, T. Minamizaki, Y. Yamashita, R. Teshima, Development of the attachment zones in 
the rat anterior cruciate ligament: changes in the distributions of proliferating cells and fibrillar 
collagens during postnatal growth, J. Orthop. Res. 20 (2002) 1339-1344. 
20. D.L. Butler, Y. Guan, M.D. Kay, et al., Location-dependent variations in the material properties 
of the anterior cruciate ligament, J. Biomech. 25 (1992) 511-518. 
21. S.G. Kim, T. Akaike, T. Sasagaw, et al., Gene expression of type I and type III collagen by 
mechanical stretch in anterior cruciate ligament cells, Cell Struct. Funct. 27 (2002) 139-144. 
22. R. Yang, J. Amir, H. Liu, B. Chaqour, Mechanical strain activates a program of genes 
functionally involved in paracrine signaling of angiogenesis, Physiol. Genomics 36 (2008) 1-14. 
23. T. Nishida, A. Maeda, S. Kubota, M. Takigawa, Role of mechanical-stress inducible protein 
Hcs24/CTGF/CCN2 in cartilage growth and regeneration: mechanical stress induces expression 
of Hcs24/CTGF/CCN2 in a human chondrocytic cell line HCS-2/8, rabbit costal chondrocytes 
and meniscus tissue cells, Biorheology 45 (2008) 289-299. 
24. Y. Kanazawa, J. Nomura, S. Yoshimoto, et al., Cyclical cell stretching of skin-derived fibroblasts 
downregulates connective tissue growth factor (CTGF) production, Connect. Tissue Res. 50 
(2009) 323-329. 
25. K.M. Heinemeier, J.L. Olesen, F. Haddad, et al., Effect of unloading followed by reloading on 
expression of collagen and related growth factors in rat tendon and muscle, J. Appl. Physiol. 106 
(2009) 178-186. 
26. H. Date, T. Furumatsu, Y. Sakoma, et al., GDF-5/7 and bFGF activate integrin α2-mediated 
cellular migration in rabbit ligament fibroblasts, J. Orthop. Res. 28 (2010) 225-231. 
27. T. Furumatsu, C. Shukunami, M. Amemiya-Kudo, et al., Scleraxis and E47 cooperatively 
regulate the Sox9-dependent transcription, Int. J. Biochem. Cell Biol. 42 (2010) 148-156. 
28. S. Omoto, K. Nishida, Y. Yamaai, et al., Expression and localization of connective tissue growth 
factor (CTGF/Hcs24/CCN2) in osteoarthritic cartilage, Osteoarthritis Cartilage 12 (2004) 
14 
 
771-778. 
29. S. Kubota, K. Kawata, T. Yanagita, et al., Abundant retention and release of connective tissue 
growth factor (CTGF/CCN2) by platelets, J. Biochem. 136 (2004) 279-282. 
30. T. Furumatsu, N. Yamaguchi, K. Nishida, et al., Endostain inhibits adhesion of endotherial cells 
to collagen I via α2β1 integrin, a possible cause of prevention of chondrosarcoma growth, J. 
Biochem. 131 (2002) 619-626. 
31. K. Saiga, T. Furumatsu, A. Yoshida, et al., Combined use of bFGF and GDF-5 enhances the 
healing of medial collateral ligament injury, Biochem. Biophys. Res. Commun. 402 (2010) 
329-334. 
32. S.J. Dangaria, Y. Ito, C. Walker, et al., Extracellular matrix-mediated differentiation of 
periodontal progenitor cells, Differentiation 78 (2009) 79-90. 
33. R. Fuchshofer, M. Birke, U. Welge-Lussen, et al., Transforming growth factor-β2 modulated 
extracellular matrix component expression in cultured human optic nerve head astrocytes, Invest. 
Ophthalmol. Vis. Sci. 46 (2005) 568-578. 
34. D. Kaneko, Y. Sasazaki, T. Kikuchi, et al., Temporal effects of cyclic stretching on distribution 
and gene expression of integrin and cytoskeleton by ligament fibroblasts in vitro, Connect. Tissue 
Res. 50 (2009) 263-269. 
35. T. Nishida, S. Kubota, T. Nakanishi, et al., CTGF/Hcs24, a hypertrophic chondrocyte-specific 
gene product, stimulates proliferation and differentiation, but not hypertrophy of cultured articular 
chondrocytes, J. Cell. Physiol. 192 (2002) 55-63. 
36. A.W. Orr, B.P. Helmke, B.R. Blackman, M.A. Schwartz, Mechanisms of mechanotransduction, 
Dev. Cell 10 (2006) 11-20. 
37. S.I. Sukharev, P. Blount, B. Martinac, et al., A large-conductance mechanosensitive channel in E. 
coli encoded by mscL alone, Nature 368 (1994) 265-268. 
38. Y. Sawada, M. Tamada, B.J. Dubin-Thaler, et al., Force sensing by mechanical extension of the 
Src family kinase substrate p130Cas, Cell 127 (2006) 1015-1026. 
15 
 
39. B. Chaqour, M. Goppelt-Struebe, Mechanical regulation of the Cyr61/CCN1 and CTGF/CCN2 
proteins, FEBS J. 273 (2006) 3639-3649. 
40. C. Schild, B. Trueb, Three members of the connective tissue growth factor family CCN are 
differentially regulated by mechanical stress, Biochim. Biophys. Acta 1691 (2004) 33-40. 
41. B. Chaqour, R. Yang, Q. Sha, Mechanical stretch modulates the promoter activity of the 
profibrotic factor CCN2 through increased actin polymerization and NF-κB activation, J. Biol. 
Chem. 281 (2006) 20608-20622. 
42. Y. Xu, D.R. Wagner, E. Bekerman, et al., Connective tissue growth factor in regulation of RhoA 
mediated cytoskeletal tension associated osteogenesis of mouse adipose-derived stromal cells, 
PLoS One 5 (2010) e11279. 
43. A. Woods, D. Pala, L. Kennedy, et al., Rac1 signaling regulates CTGF/CCN2 gene expression via 
TGFbeta/Smad signaling in chondrocytes, Osteoarthritis Cartilage 17 (2009) 406-413. 
 
 
16 
 
Figure legends 
 
Fig. 1. CCN2/CTGF in human ACL. (A) Midsubstance region of ACL (HE). (B) ACL-to-bone 
interface (tibial insertion, HE). (C) CCN2/CTGF was not observed in midsubstance region by 
immunohistochemical analysis. (D) CCN2/CTGF was detected in the cells of ACL-to-bone interface 
(tibial insertion, brown). Insets in panels C and D show magnified images of the areas indicated by 
rectangles. (E and F) CCN2/CTGF was observed in/on the interface cells: E, tibial interface; F, 
femoral interface. Inset in panel E denotes a negative control in the absence of anti-CCN2/CTGF 
antibody. Arrowheads indicate the positive signals of CCN2/CTGF in femoral interface. Bars, 100 
μm. 
 
Fig. 2. (A) Phase-contrast microscopic views of fibroblastic midsubstance cells and chondrocytic 
interface cells. Bars, 100 μm. (B) CCN2/CTGF expression in vivo and in vitro evaluated by RT-PCR 
analysis. Although CCN2/CTGF expression was detected in tissue samples of ACL interface, it was 
decreased in cultured interface cells. Effect of CTS on CCN2/CTGF and COL1A1 expression in ACL 
cells as evaluated by end-point RT-PCR (C) and by real-time PCR analyses (D). CTS (0.5 Hz, 10% 
strain, 2 h) enhanced CCN2/CTGF expression up to a 2.2-fold level of control only in interface cells 
(D, right panel), whereas COL1A1 expression was increased by CTS in both interface and 
midsubstance cells (C and E). ELISA revealed that CTS treatment increased CCN2/CTGF secretion 
from interface cells (F). However, CTS did not increase CCN2/CTGF gene expression and 
CCN2/CTGF protein secretion in midsubstance cells (D and F). * p < 0.05 compared with each 
0-h-control. 
 
Fig. 3. Effect of exogenous CCN2/CTGF on ACL cells. (A-C) Effect on CCN2/CTGF and COL1A1 
expression evaluated by RT-PCR (A) and real-time PCR (B and C) analyses. Recombinant 
CCN2/CTGF enhanced the expression of endogenous CCN2/CTGF in interface cells (A and B). 
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CCN2/CTGF treatment did not stimulate endogenous CCN2/CTGF expression in midsubstance cells 
(A and B). COL1A1 expression was not influenced by CCN2/CTGF treatment in interface cells despite 
CCN2/CTGF stimulated COL1A1 expression up to 2.4-fold level of control in midsubstance cells (C). 
(D) CCN2/CTGF stimulated the proliferation of interface cells in a dose-dependent manner. * p < 0.05 
compared with the index of 0 ng/ml control. 
 
Supplemental Fig. Different patterns of gene expression in response to CTS. In midsubstance cells, 
COL1A1 expression was increased under 5 and 10% CTS conditions (0.5 Hz, 2 h). In interface cells, 
10% CTS stimulated the expression of CCN2/CTGF and COL1A1 genes. On the other hand, higher 
stretching force (15% strain) decreased these gene expressions in both midsubstance and interface 
cells. 
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